Top Tweets for #ASH2026

about 11 hours ago

Excited to see JBI-802 featured at #ASH26 The emerging clinical data continue to strengthen our conviction in its potential to deliver meaningful benefit for patients with MPNs. Looking forward to the discussions at #ASH2026 and to what comes next.

Mehak Trehan

@mehak_trehan

1 day ago

𝗧𝘂𝗿𝗻𝗶𝗻𝗴 𝗣𝗮𝗴𝗲𝘀 𝗧𝘂𝗲𝘀𝗱𝗮𝘆 | #ASH2026 edition 𝟭𝟬 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁𝘀 𝗜’𝗺 𝘄𝗮𝘁𝗰𝗵𝗶𝗻𝗴 𝗳𝗿𝗼𝗺 𝗜𝗻𝗱𝗶𝗮 With teclistamab (Tec), elranatamab (Elra), talquetamab (Tal) and SC Dara in our toolkit, my questions are about sequencing, duration, safety and access. 𝟭. 𝗠𝗼𝗻𝘂𝗺𝗲𝗻𝗧𝗔𝗟-𝟲 | #426 At 13.4 months’ median follow-up, Tec+Tal vs EPd/PVd: PFS HR 0.11; Tal+Pom also improved PFS/OS. ~80% were anti-CD38-refractory. Watch the planned 26-cycle bispecific cap and immunoglobulin replacement burden. 𝟮. 𝗠𝗮𝗴𝗻𝗲𝘁𝗶𝘀𝗠𝗠-𝟱 | #424 Elra vs DPd: PFS HR 0.56. Only 5.9% had prior anti-CD38 exposure: important when interpreting this for Dara-refractory relapse. 𝟯. 𝗪𝗵𝗶𝗰𝗵 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗻𝗲𝘅𝘁? | #2205 In a retrospective 187-patient series, 136 target-switchers had median PFS ~4 months with the second bispecific. Activity remains possible; the best order is unresolved. 𝟰. 𝗖𝗮𝗻 𝘄𝗲 𝘀𝘁𝗼𝗽 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝘀? | #845 43 selected responders stopped; 12-month treatment-free PFS was 85.4%. Relevant to financial and infectious toxicity; selection bias limits conclusions. 𝟱. 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 | #2275 Modelled 1-year grade ≥3 infection risk: 21.0% with continuous vs 38.3% with observed immunoglobulin replacement. Supportive care belongs in the budget; replacement was not randomized. 𝟲. 𝗪𝗵𝗼 𝘀𝗵𝗼𝘂𝗹𝗱 𝗿𝗲𝗰𝗲𝗶𝘃𝗲 𝗧𝗮𝗹? | #934 Among 43 IHC-evaluable Tal patients, none of 19 with low/negative GPRC5D responded. Could pretreatment IHC improve selection? Retrospective data need validation. 𝟳. 𝗣𝗘𝗥𝗦𝗘𝗨𝗦 | #111 After ASCT, 236 patients stopped Dara per protocol; lenalidomide continued. Eligibility required ≥24 months maintenance, ≥CR and ≥12 months sustained MRD negativity by serial NGS. 𝟴. 𝗔𝗤𝗨𝗜𝗟𝗔 | #112 In high-risk smoldering MM, 7-year OS: 87.8% vs 78.7% with 3 years of SC Dara vs monitoring. Risk definitions and reliable follow-up are central before treating asymptomatic patients. 𝟵. 𝗕𝗲𝗹𝗮𝗻𝘁𝗮𝗺𝗮𝗯 𝗲𝘆𝗲 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 | #419 A 30-patient BelaRd study in newly diagnosed MM tests symptom-guided dosing. Both groups still had eye examinations. A practical implementation question for belantamab. 𝟭𝟬. 𝗘𝗫𝗖𝗔𝗟𝗜𝗕𝗘𝗥-𝗥𝗥𝗠𝗠: 𝗶𝗯𝗲𝗿𝗱𝗼𝗺𝗶𝗱𝗲 | #114 IberDd vs DVd: 10⁻⁵ flow MRD-negative CR, 41.1% vs 20.7%. PFS results await presentation. A CELMoD future-access watch: 84.3% grade 3/4 neutropenia; anti-CD38-refractory patients excluded. For MRD, 10⁻⁵ is not 10⁻⁶; matching sensitivity also does not automatically make flow and NGS interchangeable for a trial’s treatment decisions. These are abstracts to examine closely, with fuller data still to come. #TurningPagesTuesday #MMsm

$mehak_trehan's tweet photo. 𝗧𝘂𝗿𝗻𝗶𝗻𝗴 𝗣𝗮𝗴𝗲𝘀 𝗧𝘂𝗲𝘀𝗱𝗮𝘆 | #ASH2026 edition 𝟭𝟬 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 𝗮𝗯𝘀𝘁𝗿𝗮𝗰𝘁𝘀 𝗜’𝗺 𝘄𝗮𝘁𝗰𝗵𝗶𝗻𝗴 𝗳𝗿𝗼𝗺 𝗜𝗻𝗱𝗶𝗮 With teclistamab (Tec), elranatamab (Elra), talquetamab (Tal) and SC Dara in our toolkit, my questions are about sequencing, duration, safety and access. 𝟭. 𝗠𝗼𝗻𝘂𝗺𝗲𝗻𝗧𝗔𝗟-𝟲 | #426 At 13.4 months’ median follow-up, Tec+Tal vs EPd/PVd: PFS HR 0.11; Tal+Pom also improved PFS/OS. ~80% were anti-CD38-refractory. Watch the planned 26-cycle bispecific cap and immunoglobulin replacement burden. 𝟮. 𝗠𝗮𝗴𝗻𝗲𝘁𝗶𝘀𝗠𝗠-𝟱 | #424 Elra vs DPd: PFS HR 0.56. Only 5.9% had prior anti-CD38 exposure: important when interpreting this for Dara-refractory relapse. 𝟯. 𝗪𝗵𝗶𝗰𝗵 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗻𝗲𝘅𝘁? | #2205 In a retrospective 187-patient series, 136 target-switchers had median PFS ~4 months with the second bispecific. Activity remains possible; the best order is unresolved. 𝟰. 𝗖𝗮𝗻 𝘄𝗲 𝘀𝘁𝗼𝗽 𝗯𝗶𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰𝘀? | #845 43 selected responders stopped; 12-month treatment-free PFS was 85.4%. Relevant to financial and infectious toxicity; selection bias limits conclusions. 𝟱. 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗽𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗼𝗻 | #2275 Modelled 1-year grade ≥3 infection risk: 21.0% with continuous vs 38.3% with observed immunoglobulin replacement. Supportive care belongs in the budget; replacement was not randomized. 𝟲. 𝗪𝗵𝗼 𝘀𝗵𝗼𝘂𝗹𝗱 𝗿𝗲𝗰𝗲𝗶𝘃𝗲 𝗧𝗮𝗹? | #934 Among 43 IHC-evaluable Tal patients, none of 19 with low/negative GPRC5D responded. Could pretreatment IHC improve selection? Retrospective data need validation. 𝟳. 𝗣𝗘𝗥𝗦𝗘𝗨𝗦 | #111 After ASCT, 236 patients stopped Dara per protocol; lenalidomide continued. Eligibility required ≥24 months maintenance, ≥CR and ≥12 months sustained MRD negativity by serial NGS. 𝟴. 𝗔𝗤𝗨𝗜𝗟𝗔 | #112 In high-risk smoldering MM, 7-year OS: 87.8% vs 78.7% with 3 years of SC Dara vs monitoring. Risk definitions and reliable follow-up are central before treating asymptomatic patients. 𝟵. 𝗕𝗲𝗹𝗮𝗻𝘁𝗮𝗺𝗮𝗯 𝗲𝘆𝗲 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 | #419 A 30-patient BelaRd study in newly diagnosed MM tests symptom-guided dosing. Both groups still had eye examinations. A practical implementation question for belantamab. 𝟭𝟬. 𝗘𝗫𝗖𝗔𝗟𝗜𝗕𝗘𝗥-𝗥𝗥𝗠𝗠: 𝗶𝗯𝗲𝗿𝗱𝗼𝗺𝗶𝗱𝗲 | #114 IberDd vs DVd: 10⁻⁵ flow MRD-negative CR, 41.1% vs 20.7%. PFS results await presentation. A CELMoD future-access watch: 84.3% grade 3/4 neutropenia; anti-CD38-refractory patients excluded. For MRD, 10⁻⁵ is not 10⁻⁶; matching sensitivity also does not automatically make flow and NGS interchangeable for a trial’s treatment decisions. These are abstracts to examine closely, with fuller data still to come. #TurningPagesTuesday #MMsm$

HemeHub

@HemeHub

2 days ago

🩸 Join HemeHub this December for our Post ASH 2026 live webinar series! Explore the latest updates in Leukemia, Lymphoma, Classical Hematology, and Myeloma through expert-led sessions. 🔗 Register: https://t.co/TJfE4YDEpq #HemeHub #ASH2026 #ASH26 #Hematology #HematologyOncology #HemeOnc #Myeloma #Leukemia #Lymphoma

HemeHub

@HemeHub

18 days ago

🩸 Schedule Update for HemeHub’s Post-ASH 2026 Live Webinar Series! Our Myeloma session will now take place on December 23, while the Leukemia, Lymphoma, and Classical Hematology sessions remain scheduled for December 21. 🔗 Register: https://t.co/TJfE4YDEpq #HemeHub #ASH2026 #PostASH2026 #Hematology #HematologyOncology #Myeloma #Leukemia #Lymphoma

410

120

Hematología Intensa

@hematointensa

2 days ago

🩸 #ASH26 | #BMT Abstracts to Watch My current list of key allogeneic hematopoietic cell transplantation abstracts to watch at #ASH2026 👇 A mix of potentially practice-changing GVHD prevention strategies, donor selection, conditioning, MRD, and emerging transplant platforms.

hematointensa's tweet photo. 🩸 #ASH26 | #BMT Abstracts to Watch
My current list of key allogeneic hematopoietic cell transplantation abstracts to watch at #ASH2026 👇

A mix of potentially practice-changing GVHD prevention strategies, donor selection, conditioning, MRD, and emerging transplant platforms. https://t.co/xBEZ58mNjp

Talha Badar @TalhaBadarMD

3 days ago

🩸 #ASH26 | #AML Abstracts to Watch (Oral) My current list of 11 AML abstracts to watch at #ASH2026 👇 #leusm A mix of potentially practice-changing frontline trials, menin inhibitors, MRD, and novel approaches in both younger and older patients. 1️⃣ Ivosidenib + intensive chemotherapy in newly diagnosed IDH1-mutated AML HOVON150/AMLSG29-18, phase 3 Superior event-free survival 📄 Abstract 0001, Press Program 📅 Sun Dec 13 | 7:00 AM CT ⚠️ Oral/plenary slot not yet confirmed 🔗 https://t.co/HAiAem9IzK 2️⃣ Gilteritinib vs midostaurin in newly diagnosed FLT3-mutated AML Subgroup analysis from HOVON156/AMLSG28-18/pasha 📄 Abstract 56 | Session 615 📅 Sat Dec 12 | 9:30 AM 📍 Great Hall BC 🔗 https://t.co/vnNwomzMZ7 3️⃣ Bleximenib in R/R AML with KMT2A rearrangements or NPM1 mutations Topline results from phase 2 CAMELOT-1 📄 Abstract 661 | Session 616 📅 Sun Dec 13 | 4:30 PM 📍 Hall B 🔗 https://t.co/Das1necevM 4️⃣ Cladribine + LDAC + venetoclax vs intensive chemotherapy (7+3) Patients ≥60 years with newly diagnosed AML 📄 Abstract 57 | Session 615 📅 Sat Dec 12 | 9:30 AM 📍 Great Hall BC 🔗 https://t.co/vuvS9OfmdF 5️⃣ Can we stop HMA + venetoclax? Discontinuation of hypomethylating agent + venetoclax in newly diagnosed AML with undetectable MRD 📄 Abstract 1009 | Session 617 📅 Mon Dec 14 | 4:30 PM 📍 Great Hall AD 🔗 https://t.co/MiP4Z7F5BL 6️⃣ Sonrotoclax + azacitidine across ELN 2024 genetic risk groups Treatment-naive AML unfit for intensive chemotherapy 📄 Abstract 60 | Session 615 📅 Sat Dec 12 | 9:30 AM 📍 Great Hall BC 🔗 https://t.co/gU3WGMcyAm 7️⃣ Venetoclax + 3-day multi-frequency decitabine vs AZA + VEN Older adults with newly diagnosed AML, updated randomized results 📄 Abstract 1012 | Session 617 📅 Mon Dec 14 | 4:30 PM 📍 Great Hall AD 🔗 https://t.co/L7cHhkZ4IF 8️⃣ Whole-genome-informed AML MRD testing Prospective multicenter validation, MEASURE 📄 Abstract 390 | Session 619 📅 Sat Dec 12 | 4:00 PM 📍 Great Hall AD 🔗 https://t.co/XPb38cdFAW 9️⃣ VEN + AZA vs daunorubicin + cytarabine induction Young adults with ELN adverse-risk AML, phase 2b 📄 Abstract 1010 | Session 617 📅 Mon Dec 14 | 4:30 PM 📍 Great Hall AD 🔗 https://t.co/T8URfhrzzg 🔟 Ziftomenib + gilteritinib in R/R NPM1- and FLT3-co-mutated AML First results from phase 1 KOMET-008 📄 Abstract 66 | Session 617 📅 Sat Dec 12 | 9:30 AM 📍 Great Hall AD 🔗 https://t.co/nTnyI2myj8 11/12 1️⃣1️⃣ FLAI-G frontline in younger FLT3-mutated AML Fludarabine + high-dose cytarabine + idarubicin + gilteritinib First interim analysis, phase 2 GIMEMA AML2924 📄 Abstract 903 | Session 617 📅 Mon Dec 14 | 2:45 PM 📍 Great Hall BC 🔗 https://t.co/OwFJZBjAnr Lots to watch at #ASH26 in AML. Particularly interested in the randomized frontline data, evolving role of menin inhibition, MRD-guided treatment decisions, and whether lower-intensity approaches can continue challenging conventional intensive chemotherapy. Which AML abstracts are on your must-see list? #AML #Leukemia #ASH26

Sabrina Ranero Ferrari @SabrinaRanero

3 days ago

What a joy to see so many #MCL abstracts at #ASH2026 going chemo-free in 1L 🙌 OASIS II, CARAMEL, GLOASIS, TrAVeRse & more. Now the real questions: durability, toxicity, TP53, fixed vs continuous duration… and access! The MCL landscape is changing fast !

Toby A. Eyre @tobyeyre82

4 days ago

Looking forward to presenting the full results in the 1L BTKi MCL session on the monday evening! Do come along at #ASH2026 #MCL

103

Toby A. Eyre @tobyeyre82

4 days ago

Looking forward to presenting the full results in the 1L BTKi MCL session on the monday evening! Do come along at #ASH2026 #MCL

Benlazar S M A @smbenlazar

4 days ago

#ASH26 #MCL Acalabrutinib and rituximab in older mantle cell lymphoma patients unfit for full dose chemoimmunotherapy: Primary analysis of the phase II caramel trial https://t.co/NmtmZpnESQ

smbenlazar's tweet photo. #ASH26 #MCL Acalabrutinib and rituximab in older mantle cell lymphoma patients unfit for full dose chemoimmunotherapy: Primary analysis of the phase II caramel trial https://t.co/NmtmZpnESQ https://t.co/0T0VenVlaf

Toby A. Eyre @tobyeyre82

4 days ago

Great summary of OASIS II - a UK, LYSA collaboration. Look out for the oral presentation of the first ever RCT in 1L MCL comparing 2 non-chemotherapy approaches on the monday evening ! #ASH2026 #MCL

Benlazar S M A @smbenlazar

4 days ago

#ASH26 #lymsm Ibrutinib plus anti-CD20 therapy with or without fixed-duration venetoclax in previously untreated mantle cell lymphoma : Primary results of OASIS-2 trial https://t.co/T6gqlhnx1G

smbenlazar's tweet photo. #ASH26 #lymsm Ibrutinib plus anti-CD20 therapy with or without fixed-duration venetoclax in previously untreated mantle cell lymphoma : Primary results of OASIS-2 trial https://t.co/T6gqlhnx1G https://t.co/xhTOjZ2iQe

Diva @Diva_Baggio

5 days ago

#ASH2026: Pullarkat et al report real-world outcomes with duvelisib in a real-world cohort of 328 patients with nodal PTCL: - ORR 46%, CRR 32% - In TFH lymphoma: ORR 58%, CRR 46% - Median duration of response 250 days - 16% proceeded to alloSCT https://t.co/UHtl0KGBoX

679

Diva @Diva_Baggio

6 days ago

#ASH2026: Eche-Ugwu et al & the PETAL consortium report the first study to report HRQL outcomes in patients with PTCL. Rates of pre-treatment HRQL similar to other lymphoma subtypes. Congratulations to the authors for working to address this important gap. https://t.co/ABFDRgupEA

407

Daisuke Minakata @D_M_kappa_MM

6 days ago

#ASH2026 iMMagine-1 update: Anito-cel in RRMM (n=117, median follow-up 18 mo). ORR 96%, CR/sCR 75%, MRD− (10⁻⁶) 76% of evaluable pts, 24-mo PFS 58%, OS 84%, ICANS 8%, No delayed/non-ICANS neurotoxicity reported

217

NMDP @nmdp_org

6 days ago

#ASH2026 NMDP/CIBMTR present: OPTIMIZE: ⬇️ dose PTCy delivered 88.7% 1-yr survival in mismatched unrelated donor transplants MEASURE: Genome-informed AML MRD testing achieved 97% sensitivity v. 31% standard care CIBMTR: MCW-NMDP research collab. https://t.co/qSPPFnyd3k

nmdp_org's tweet photo. #ASH2026 NMDP/CIBMTR present:
OPTIMIZE: ⬇️ dose PTCy delivered 88.7% 1-yr survival in mismatched unrelated donor transplants
MEASURE: Genome-informed AML MRD testing achieved 97% sensitivity v. 31% standard care
CIBMTR: MCW-NMDP research collab. https://t.co/qSPPFnyd3k https://t.co/ehIkSlpK4d

718

Terry Glassman @TerryGlassman

6 days ago

Fellow #myeloma patients! I'll be attending #ASH2026 with the @IMFmyeloma Patients at ASH team! ❤️ Follow me for the latest research updates, key takeaways, and the patient perspective. Have questions you'd like me to explore? Let me know! #IMFASH26

TerryGlassman's tweet photo. Fellow #myeloma patients!

I'll be attending #ASH2026 with the @IMFmyeloma Patients at ASH team! ❤️

Follow me for the latest research updates, key takeaways, and the patient perspective.

Have questions you'd like me to explore? Let me know!

#IMFASH26 https://t.co/TxmvTeoCCc

281

HemeHub

@HemeHub

6 days ago

🩸 Mark your calendars for HemeHub’s Post-ASH 2026 live webinar series this December! Join us for expert-led updates in Leukemia, Lymphoma, Classical Hematology, and Myeloma. 🔗 Register: https://t.co/TJfE4YEceY #HemeHub #ASH2026 #ASH26 #Hematology #HematologyOncology #HemeOnc #Myeloma #Leukemia #Lymphoma

HemeHub

@HemeHub

18 days ago

410

185

EasyM: Blood-based MRD for MM

@easym_test

6 days ago

📢 Exciting News - Abstracts for #ASH2026 are posted!!! We are proud to be presenting our research this year investigating our mass spectrometry (MS) based assay for the quantification of soluble B-cell maturation antigen (sBCMA) in multiple myeloma (MM) serum samples. 💡 The study found that our MS-based assay had good correlation to sBCMA ELISA in MM patients, demonstrating the potential to monitor disease burden in MM patients, regardless of their M-protein type. In addition, we collaborated on a study with Washington University School of Medicine in St. Louis, to describe post-chimeric antigen receptor (CAR) T cell M-protein kinetics, using clonotypic mass spectrometry (CT-MS). 💡 Findings demonstrate that CT-MS is highly sensitive for relapse, with detectable and increasing M-protein in 100% of relapse samples. Achieving undetectable CT-MS was highly dependent on M-protein half-life. Read the full abstracts here: 4067: Mass Spectrometry Assay to Quantify B-Cell Maturation Antigen in Serum of Patients with Multiple Myeloma: https://t.co/zuok9rRida 4071: M-Protein Kinetics via Clonotypic Mass Spectrometry Following BCMA-Directed CAR T Cell Therapy: https://t.co/0Kpb6dbijn #MultipleMyeloma #MM #MRD #MinimalResidualDisease #MMSM #CART #BCMA #MassSpec

easym_test's tweet photo. 📢 Exciting News - Abstracts for #ASH2026 are posted!!!

We are proud to be presenting our research this year investigating our mass spectrometry (MS) based assay for the quantification of soluble B-cell maturation antigen (sBCMA) in multiple myeloma (MM) serum samples.

💡 The study found that our MS-based assay had good correlation to sBCMA ELISA in MM patients, demonstrating the potential to monitor disease burden in MM patients, regardless of their M-protein type.

In addition, we collaborated on a study with Washington University School of Medicine in St. Louis, to describe post-chimeric antigen receptor (CAR) T cell M-protein kinetics, using clonotypic mass spectrometry (CT-MS).

💡 Findings demonstrate that CT-MS is highly sensitive for relapse, with detectable and increasing M-protein in 100% of relapse samples. Achieving undetectable CT-MS was highly dependent on M-protein half-life.

Read the full abstracts here:

4067: Mass Spectrometry Assay to Quantify B-Cell Maturation Antigen in Serum of Patients with Multiple Myeloma: https://t.co/zuok9rRida

4071: M-Protein Kinetics via Clonotypic Mass Spectrometry Following BCMA-Directed CAR T Cell Therapy: https://t.co/0Kpb6dbijn

#MultipleMyeloma #MM #MRD #MinimalResidualDisease #MMSM #CART #BCMA #MassSpec

PETAL Consortium @mghpetal

6 days ago

@mghpetal has 5 abstracts accepted to the 2026 @ASH_hematology Annual Meeting! 🌸 Read more: https://t.co/Qn3azNF4vm #ASH2026

Ben Fidler @BentheFidler

6 days ago

At ASH, drugmakers to showcase early data for three-pronged cancer therapies https://t.co/Z2t74F90x7 @ByJonGardner #ASH2026 $ABBV $JNJ

421

Nurix Therapeutics @Nurix_Tx

7 days ago

Nurix will report new and updated efficacy and safety data from the ongoing Phase 1a/1b study evaluating our investigational oral BTK degrader, bexobrutideg, in patients with relapsed/refractory CLL/SLL in a poster session at #ASH2026. More details here: https://t.co/koJdGNMnDR

$Nurix_Tx's tweet photo. Nurix will report new and updated efficacy and safety data from the ongoing Phase 1a/1b study evaluating our investigational oral BTK degrader, bexobrutideg, in patients with relapsed/refractory CLL/SLL in a poster session at #ASH2026. More details here: https://t.co/koJdGNMnDR https://t.co/Dtc1dnK8qP$

165

SFS @SantiagoFS_

7 days ago

Our #ASH2026 abstract is now online How does limited access to molecular testing affect AML risk stratification and outcomes? We explored this question using 10 years of real-world data from Colombia. 🇨🇴 Abstract #4579 https://t.co/tgXAl2juYJ

209

PharmaShots | Iluminate.Innovate.Inspire

@Pharmashot

7 days ago

@VerismoTx to Present P-I (CELESTIAL-301) Data of SynKIR-310 for R/R B-Cell Non-Hodgkin Lymphoma at ASH 2026. #VerismoTherapeutics #SynKIR310 #ASH2026 #Phase1Trial #Pharmashots #CellTherapy #Oncology #Hematology https://t.co/8BoXkusq4T

Top Tweets for #ASH2026

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users